Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Announces Internal Review Likely To Result In Staff, Program Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.

You may also be interested in...



Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit

Alnylam Pharmaceuticals' strategy announcement on Jan. 7 was “a transformation,” CEO John Maraganore said in an interview at the J.P. Morgan Healthcare Conference, emphasizing that he has “never been more excited” about the prospects for his company.

Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit

Alnylam Pharmaceuticals' strategy announcement on Jan. 7 was “a transformation,” CEO John Maraganore said in an interview at the J.P. Morgan Healthcare Conference, emphasizing that he has “never been more excited” about the prospects for his company.

Chugai To Remain Unscathed By Roche's Internal Restructuring And Cost-cutting Measures

TOKYO - Roche Group is in the process of reviewing and implementing a group-wide productivity and cost reduction program, but Japanese partner Chugai will not be directly impacted by the initiative, according to Roche's CEO

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel